Brief: MannKind Announces Completion Of Enrollment In U.S. Phase 4 INHALE-3 Trial In Patients Living With Type 1 Diabetes
06/11/2023 11:20
Nov 6 (Reuters) - MannKind Corp MNKD.O :
* MANNKIND ANNOUNCES COMPLETION OF ENROLLMENT IN U.S. PHASE
4
INHALE-3 CLINICAL TRIAL IN PATIENTS LIVING WITH TYPE 1 DIABETES
* MANNKIND CORP: INITIAL STANDARDIZED MEAL DATA FROM
INHALE-3 ON
TARGET FOR PRESENTING IN 1Q 2024 FOLLOWED BY PRIMARY ENDPOINT
ANALYSIS IN 2Q 2024
Source text for Eikon: ID:nGNX1VsNzb
Further company coverage: MNKD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children